NECLIFEPharmaceuticals
Nectar Lifesciences Ltd — PE Ratio & Valuation Analysis
₹9.30
-7.74%
Current P/EN/AxPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E99.5x100.0% below avg
✅
100.0% Discount to Industry
NECLIFE P/E N/Ax vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2024 | ₹0.22 | ₹39 | 177.2x |
| 2022 | ₹1.12 | ₹25 | 21.9x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Nectar Lifesciences Ltd Valuation
Nectar Lifesciences Ltd (NECLIFE) currently trades at N/Ax earnings. The Pharmaceuticals sector average PE is 31.77x. Historically, NECLIFE has traded at an average PE of 99.5x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
-11.23%
Dividend Yield
0.00%
More on Nectar Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.